International Non-Proprietary Names (INN) are the globally recognized generic names for pharmaceutical substances designated by the World Health Organization. For B.Pharm students, mastering INN, generic names, drug nomenclature, WHO INN Programme, and common INN stems is essential for safe prescription writing, pharmacovigilance, drug regulation, and rational pharmacotherapy. Understanding how INN differ from brand names, how stems indicate therapeutic classes (for example -pril, -olol, -mab), and the INN assignment process helps in drug identification, dispensing, and avoiding medication errors. This topic links pharmacology, medicinal chemistry, and pharmacy practice. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary purpose of an International Non‑Proprietary Name (INN)?
- To identify the manufacturer of a drug
- To provide a unique, universally recognized generic name for an active pharmaceutical substance
- To serve as a trademark for marketing
- To specify the exact formulation and excipients of a product
Correct Answer: To provide a unique, universally recognized generic name for an active pharmaceutical substance
Q2. Which organization is responsible for assigning INNs?
- FDA (Food and Drug Administration)
- EMA (European Medicines Agency)
- WHO INN Programme
- USP (United States Pharmacopeia)
Correct Answer: WHO INN Programme
Q3. INN stems (common endings) are used primarily to:
- Indicate the manufacturer’s country
- Show the salt form of the drug
- Suggest a pharmacological or chemical relationship among drugs
- Specify the route of administration
Correct Answer: Suggest a pharmacological or chemical relationship among drugs
Q4. Which INN stem is commonly used for angiotensin‑converting enzyme (ACE) inhibitors?
- -sartan
- -pril
- -olol
- -prazole
Correct Answer: -pril
Q5. The INN suffix “-mab” indicates which class of drugs?
- Small‑molecule antivirals
- Cytostatic chemotherapy agents
- Monoclonal antibodies
- Non‑steroidal anti‑inflammatory drugs
Correct Answer: Monoclonal antibodies
Q6. Which statement about INN and brand names is correct?
- INN and brand names are always identical
- Brand names are assigned by WHO
- INN are non‑proprietary; brand names are proprietary marketed names
- INN can only be used after patent expiry
Correct Answer: INN are non‑proprietary; brand names are proprietary marketed names
Q7. The INN stem “-olol” typically identifies which therapeutic class?
- Statins
- Beta‑adrenergic blockers
- Calcium channel blockers
- Antifungal agents
Correct Answer: Beta‑adrenergic blockers
Q8. How are salt or ester forms of an active moiety handled in INN nomenclature?
- Each salt gets its own independent INN unrelated to the parent moiety
- INN are assigned to the active moiety; salts/esters are indicated by adding the salt/ester designation
- Salts are banned from INN lists
- INN always include the salt name within the core INN
Correct Answer: INN are assigned to the active moiety; salts/esters are indicated by adding the salt/ester designation
Q9. Which INN stem is commonly found in HMG‑CoA reductase inhibitors (statins)?
- -sartan
- -statin
- -cillin
- -azole
Correct Answer: -statin
Q10. The INN “atenolol” indicates what about the drug name?
- It is a brand name assigned by a company
- It is an INN representing a beta‑blocker with the stem -olol
- It specifies a salt form only
- It is used only in one country
Correct Answer: It is an INN representing a beta‑blocker with the stem -olol
Q11. Which of the following is a correct reason for using INNs in prescriptions and drug information?
- To promote a specific pharmaceutical company
- To ensure consistent identification of active substances, reducing medication errors
- To hide the chemical nature of the drug
- To avoid international trade regulations
Correct Answer: To ensure consistent identification of active substances, reducing medication errors
Q12. The INN stem “-sartan” designates which class of drugs?
- ACE inhibitors
- Angiotensin II receptor blockers (ARBs)
- Proton pump inhibitors
- Antidepressants
Correct Answer: Angiotensin II receptor blockers (ARBs)
Q13. Which of the following is true about harmonization between INN and national non‑proprietary names (e.g., USAN)?
- INN are always different from national names
- Harmonization efforts aim to align INN and national names to reduce confusion
- National names override INN by law everywhere
- USAN is assigned by WHO
Correct Answer: Harmonization efforts aim to align INN and national names to reduce confusion
Q14. The INN stem “-azole” most commonly indicates which therapeutic group?
- Antifungals
- Antihypertensives
- Analgesics
- Anticoagulants
Correct Answer: Antifungals
Q15. Which of the following best describes how INN address biological medicines and biosimilars?
- All biologicals are given the same INN regardless of structure
- Specific INN policies and suffixes may be used to identify biologicals and distinguish biosimilars when needed
- Biologicals cannot receive INNs
- INN always include the manufacturer’s name for biologicals
Correct Answer: Specific INN policies and suffixes may be used to identify biologicals and distinguish biosimilars when needed
Q16. Which INN stem is associated with proton pump inhibitors?
- -cillin
- -prazole
- -mab
- -vir
Correct Answer: -prazole
Q17. The INN “oseltamivir” indicates it is an antiviral drug because of which stem?
- -vir
- -olol
- -pril
- -statin
Correct Answer: -vir
Q18. When a new active substance is proposed for an INN, the WHO INN Programme typically:
- Automatically adopts the sponsor’s proprietary name as INN
- Reviews the proposal, ensures uniqueness and safety, and publishes a proposed INN for public comment
- Assigns the INN without consultation
- Requires the substance to be already marketed internationally
Correct Answer: Reviews the proposal, ensures uniqueness and safety, and publishes a proposed INN for public comment
Q19. Which of the following is a safety rationale used by INN naming conventions?
- Choosing names that are visually and phonetically similar for related drugs
- Avoiding names that could be confused in prescribing or dispensing
- Using complex proprietary terms to prevent copying
- Restricting names to Latin only
Correct Answer: Avoiding names that could be confused in prescribing or dispensing
Q20. The INN stem “-cillin” is typically used for which antibiotic class?
- Cephalosporins
- Macrolides
- Penicillins
- Fluoroquinolones
Correct Answer: Penicillins
Q21. Which statement about the scope of an INN is correct?
- INN specify manufacturing methods and excipients
- INN name the active pharmaceutical substance or active moiety, not the full pharmaceutical product
- INN include dosage regimen recommendations
- INN always include the route of administration
Correct Answer: INN name the active pharmaceutical substance or active moiety, not the full pharmaceutical product
Q22. The INN stem “-mycin” is commonly seen in which group of antibiotics?
- Macrolides and aminoglycosides (varies by agent)
- Beta‑lactams exclusively
- Antifungals
- Antivirals
Correct Answer: Macrolides and aminoglycosides (varies by agent)
Q23. Why might an INN include a Greek or Latin derived stem rather than a commercial-sounding term?
- To make names harder to pronounce
- To reflect chemical or pharmacological meaning and enhance international intelligibility
- To protect manufacturer trademarks
- To indicate pricing
Correct Answer: To reflect chemical or pharmacological meaning and enhance international intelligibility
Q24. Which of the following best describes a “recommended INN” versus a “proposed INN”?
- Recommended INN are tentative; proposed INN are final
- Proposed INN are published for comment; recommended INN have completed review and are endorsed by WHO
- They are interchangeable terms with no difference
- Recommended INN are only for over‑the‑counter drugs
Correct Answer: Proposed INN are published for comment; recommended INN have completed review and are endorsed by WHO
Q25. Which INN stem is commonly associated with fluoroquinolone antibiotics?
- -floxacin
- -azole
- -pril
- -mab
Correct Answer: -floxacin
Q26. If a new small molecule drug is a stereoisomer of an existing drug, INN policy may allow:
- Use of the exact same INN without distinction
- Distinct INN or a modified name to reflect stereochemistry (e.g., prefixes or different root)
- Refusal to name the new molecule
- Assigning the manufacturer’s trade name as the INN
Correct Answer: Distinct INN or a modified name to reflect stereochemistry (e.g., prefixes or different root)
Q27. Which of the following is true about the publication of INN lists?
- INN lists are secret and available only to manufacturers
- WHO publishes INN lists and proposed names for transparency and public comment
- INN lists are issued by national governments only
- INN lists are updated only once every fifty years
Correct Answer: WHO publishes INN lists and proposed names for transparency and public comment
Q28. The INN stem “-pramine” is commonly associated with which class of drugs?
- Tricyclic antidepressants
- Beta blockers
- Anticoagulants
- Antifungals
Correct Answer: Tricyclic antidepressants
Q29. How do INNs contribute to pharmacovigilance and medication safety?
- By obscuring drug identity from healthcare professionals
- By providing consistent names to identify adverse reactions and avoid confusion across countries and products
- By replacing all brand names in advertising
- By standardizing pricing
Correct Answer: By providing consistent names to identify adverse reactions and avoid confusion across countries and products
Q30. Which of the following statements about INN and biosimilars is correct?
- Biosimilars always use the exact same INN as their reference biological without additional distinction
- INN policies may include distinctive suffixes or qualifiers to ensure traceability of biologicals and biosimilars when needed
- Biosimilars are not allowed to have INNs
- INN identifies the manufacturing process of biosimilars
Correct Answer: INN policies may include distinctive suffixes or qualifiers to ensure traceability of biologicals and biosimilars when needed
